Revenue surge masks margin collapse; profit turned negative
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Guided 16%+ PBDIT; delivered 9.8% OPM. Revenue guidance (₹500 Cr / 33% growth) on track, but margin guidance materially undershooting.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Synergy delivered 60.8% YoY revenue growth, beating its own 33% guidance, and secured major OEM wins (Nordex, Vestas). However, a net loss of ₹5.1 Cr in Q2—despite volume strength—reveals severe execution challenges. Prior guidance of 16%+ PBDIT margins is being missed badly (delivered 9.8% OPM); management blames 50% raw-material inflation and logistics costs but hasn't formally cut guidance. Greenfield capex and cost stabilization are contingent, not certain.
₹115.8 Cr
Revenue · +60.8% YoY₹-5.1 Cr
Reported PAT · −315.3% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
33% FY27 revenue growth maintained
METQ2 YoY revenue +60.8%, H1 +25.8% (paced above guidance)
16%+ PBDIT margins expected for full year
OVERSTATEDQ2 OPM 9.8%, NPM -4.4%, H1 PBDIT 8.9% (vs prior 15.6%)
Inventory buildup will not impact current-quarter revenue
METConfirmed: production +25.8% YoY, revenue +20.2% QoQ; inventory sits as balance-sheet cost
Export revenues expected to grow 50% this year
METStated in call; exports currently 25% → targeting 30% of revenue. Corroborated by Nordex/Vestas order wins
80% capacity utilization achievable for FY27
METH1 at 75%, targeting 85% by year-end, weighted ~80% full year; on track
Earnings quality
What changed since the last call
Revenue growth beat prior guidance
UpgradeFY27 guidance: 33% growth. Delivered: Q2 +60.8% YoY, H1 +25.8%. Paced above 33% full-year trajectory, driven by stronger export demand and OEM traction.
Margin guidance missed severely in H1
DowngradePrior: 16%+ PBDIT target. Delivered: H1 8.9%, Q2 10.2%. Driven by 50% input cost inflation and elevated logistics. Management now guiding H2 17-18% EBITDA (vs prior 16%+ baseline), implying ~12-13% blended full-year—below guidance.
Net loss in Q2 vs prior expectation of profitability
DowngradeDelivered -₹5.1 Cr PAT in Q2. Management had not pre-warned of loss. Deflected with EBITDA argument when pressed; targeting 'half-a-percent profit or 0.5% loss' by year-end.
OEM order book materially expanded
UpgradeNew wins: Nordex (200+ crores order booked for exports, US market), Vestas (confirmed), Siemens Gamesa, Envision (in development). Vestas and Nordex capacity constraints imply strong pull-through demand.
Export revenue mix rising faster than expected
UpgradePrior: 25% of revenue. Now targeting 30% + 50% growth in export revenues. US market shift (GE sold to Nordex) creates non-Chinese supply gap, favoring India. Tariff advantage vs China aids pricing power.
Greenfield project delayed from 'by Mar 2028' to '15-18 months out'
NeutralLand acquisition + stabilization of existing 45k-ton capacity takes priority. Greenfield now 2-3 years from project start, not immediate. Capacity constraints cited as 'execution challenge,' not demand issue.
The Q&A
Analysts pressed hard: Nitin Dharmawat questioned margin miss (8% from commodities, 20-30% logistics); Girish directly challenged net profit negativity; Rajas Joshi probed inventory, currency impact, electricity cost; Samarth questioned competitive capacity expansion and pricing power. ED held firm on demand and cost passthrough, but retreated to EBITDA when cornered on losses. Tone: defensive but not evasive. Q&A tone: analytical, not hostile.
Revenue guidance & H2 outlook — Nitin Dharmawat, Investor
AnsweredWe see capacity of 150 crores + turnover; no challenge meeting 500 crores. Second half revenue expected 300+ crores. Demand trajectory is positive.
PBDIT margin recovery timeline — Nitin Dharmawat, Investor
PartialInitially guided 16% (13% base + 300 bps improvement). Raw material inflation hit 8%, offsetting gains. H2 expecting 17-18% EBITDA, 100 basis point growth YoY. Cost stabilization contingent on input normalization.
Inventory buildup impact — Nitin Dharmawat, Investor
AnsweredDoes not show in revenue; will show as inventory cost on balance sheet. Sitting at cost price. Shipping constraint (Vestas, Maersk tie-ups) delaying realization. October showing 60-70% shipment momentum; should ease in Q3.
Export revenue acceleration — Nitin Dharmawat, Investor
AnsweredYes. GE exited, Nordex entered US market. Nordex order book is very good; Vestas same. US tariff advantage vs China favors India. Export growth 50% this year; will reach 30% of revenue (from 25%). Europe has good order book but no tariff edge vs China.
Competitive & China cost pressure — Nitin Dharmawat, Investor
AnsweredRupee down 25% vs RMB in 18 months. Cost escalation in China same as India. Chinese cost competitiveness is lower. OEMs pushing localization, non-Chinese casting systems. Synergy is major supply chain for US market. No challenge from Chinese imports.
Net profit negativity — Girish, Investor
PartialLook at EBITDA than profit (depreciation on capex sits on balance sheet forever). EBITDA growing 50%. By year-end, targeting 0.5% loss or half-a-percent profit. H2 should see significant profit uplift if capacity utilization and price correction happen. Contingent on inventory rundown and input stabilization.
Electricity cost spike — Rajas Joshi, Investor
AnsweredElectricity tariff increased 20% in Maharashtra (renewable energy verdict cost). Cost retrospectively charged by MSEDCL for last two years; recovered now. Wind open access reduces cost by 7-8 rupees/unit vs captive solar. No further one-offs in Q2.
Capacity expansion & demand risk — Samarth, Investor
AnsweredDemand far exceeds capacity. Even if competitor doubles, demand exceeds. Non-wind side: growing but minority. Focus is maximizing wind/OEM traction. Nordex & Vestas alone can absorb entire capacity; new OEMs (Siemens, Envision, Adani) also onboarded. Capacity constraint, not demand constraint.
Greenfield project capex & equity dilution — Gulam Soni, Investor
PartialFirst priority: stabilize and absorb current 45k-ton capacity, then expand. Greenfield 2-3 years out. When we do capex, we can raise funds, but market cap matters. Strategy: build market first, then expand; not expand blindly and dilute at lower valuations.
Capacity utilization path — Javed Pinjari, Investor
Partial600-650 is bandwidth with 80% utilization. With greenfield, 30-35% CAGR is feasible. But greenfield is 15-18 months away. Near-term: FY27 revenue protected at 29 crores (typo in transcript, likely ₹500 crores). FY28 will see greenfield ramp. Don't want to over-leverage without stabilizing current operations.
Guidance
FY27 ₹500 Cr revenue (33% YoY growth)
HighConfirmed in call. H1 ₹192 Cr, H2 targeting 300+ crores = 492-500 Cr FY27. On track despite input cost headwinds.
FY27 PBDIT 16%+ (prior guidance)
LowH1 delivered 8.9%, Q2 10.2%. Management now guiding H2 17-18% EBITDA, implying ~12-13% blended full-year (below 16% prior).
H2 FY27 EBITDA 17-18%
MediumContingent on input cost stabilization (raw material prices, logistic cost normalization) and inventory rundown. Price indexation for CRC, pig iron kicks in Q3.
Machine shop investment ongoing; greenfield land acquisition 15-18 months
MediumNo formal capex amount disclosed. Greenfield likely ₹50-100 Cr+ over 2-3 years. Financing to be raised opportunistically, not immediately.
Risks the call surfaced
Input cost inflation & margin pressure
HighRaw material (furan resin, pig iron, CRC) inflation 50%+; logistics costs up 20-30%. Contracts lock pricing for 12 months; passthrough lagged. If costs don't stabilize, FY27 margins will remain <10%.
Inventory & working capital build
HighUnshipped inventory buildup (production +25.8% vs revenue +20.2%) due to shipping constraints (Maersk, ODC delays, war-induced capacity). Inventory sits as balance-sheet cost; revenue realization delayed to Q3. If shipping constraints persist, cash burn accelerates.
Net profitability & capex depreciation burden
HighQ2 net loss ₹5.1 Cr (PAT -₹5.1 Cr, NPM -4.4%) despite ₹115.8 Cr revenue. Heavy capex (machine shop, facilities) is depreciating on P&L, masking EBITDA profit. Risk: if margins don't recover to 16%+ guidance, EBITDA growth will slow and cash profit remains squeezed. Company deflected analyst question on when PAT turns positive.
Customer concentration & OEM order pull-through
MediumNordex & Vestas account for bulk of new order wins. Company claims demand exceeds capacity, but if Nordex/Vestas capex cycles slow (renewable energy cycle risk) or if US tariff policy shifts, order book could deflate rapidly. Currently demand stated as 60k+ tons vs 45k capacity; little buffer.
Greenfield capex execution & funding risk
MediumGreenfield project (100k-ton capacity, 15-18 months to land acquisition, 2-3 year full timeline) is contingent on stabilizing current operations and raising capital opportunistically. No formal capex budget disclosed. Risk: if market cap compresses or debt covenants tighten, capex stalls and competitive capacity expansion (e.g., South Beater's 3x expansion) could capture market share.
Currency & geopolitical risk
MediumRupee down 25% vs RMB in 18 months; benefits export competitiveness but elevates capex costs. War-induced shipping delays (Black Sea, insurance premiums) impacting supply chain. Chinese casting makers are cost-competitive if tariffs shift or geopolitical tension eases.
Management
Score 6/10. ED candid on cost headwinds (inflation, logistics, electricity) but deflects net loss concern to EBITDA. Clear on segment performance, OEM traction, but vague on greenfield capex timeline/cost. AVP (Shreya) provides good industry context. FY27 revenue guidance on track (Q2 +60.8% YoY). Margin guidance undershooting badly (9.8% OPM vs 16%+ prior). Profitability lagging: -₹5.1 Cr net loss in Q2 despite volume growth. Machine shop investment near completion but integration risk remains.
1 · Q3 FY27 (next quarter)
Input cost stabilization + inventory clearance + H2 export ramp (targeting 50% growth)
2 · H2 FY27 (6 months)
PBDIT margin recovery toward 17-18% EBITDA; price indexation for CRC/pig iron kicks in Q3
3 · Mar 2028 (15-18 months)
Greenfield project land acquisition + initial capacity expansion (100k-ton target)
Greenfield capex and cost stabilization are contingent, not certain.
Synergy Green swings to ₹5.1 Cr loss as 61% YoY revenue surge is swamped by capex-led D&A, interest spike
revenue +60.8% · margins compressing
₹115.78 Cr
+60.8% YoY
₹-5.08 Cr
-4.37%
-7.5pp YoY
₹-3.27
Synergy Green Industries posted consolidated revenue of ₹115.78 Cr for Q2 FY27, up 60.8% YoY and 54.1% QoQ — its highest quarterly revenue on record — but net profit swung to a loss of ₹5.08 Cr versus a ₹2.36 Cr profit in Q2 FY26, with OPM (PBDIT margin) compressing to 9.77% from 12.96% a year ago. Sequentially the picture improved: the loss narrowed from ₹10.11 Cr in Q1 FY27 and PBDIT margin rose from 6.30%, but YoY is the primary read here and that trend is a profit-to-loss swing, not growth. This is a micro-cap with no tracked analyst coverage; a search turned up no consensus estimate or preview for this specific quarter, so vsStreet is unknown rather than a miss or beat.
Q2 FY-2027 vs prior quarters
The driver is capitalised capex, not operations. Depreciation & amortisation nearly tripled YoY to ₹9.97 Cr from ₹3.66 Cr, and finance costs rose 52.2% YoY to ₹7.15 Cr from ₹4.70 Cr — together adding roughly ₹8.76 Cr of incremental cost versus last year, more than enough on its own to explain the swing to loss. Capital work-in-progress fell to ₹1.47 Cr from ₹47.46 Cr at FY26-end while gross property, plant and equipment rose to ₹282.19 Cr, confirming new capacity has been capitalised and is now depreciating and drawing interest ahead of utilisation catching up. Core operating costs tracked revenue broadly in line (cost of materials +47.3% YoY, other expenses +59.1% YoY), so the margin pressure sits squarely on the D&A and finance-cost lines, not raw material or labour inflation.
The stock went into the print at ₹546.75, down 10.9% over the past month of trading.
FY27 revenue ₹500 Cr (33% growth), PBDIT margins to expand 300+ bps to 16%+. Land for 100k-ton capacity targeted by Mar 2028. Capacity utilization target 80% for FY27.
— This quarter: missed
Against management's own August-2026 guidance — FY27 revenue of ₹500 Cr (33% growth) and PBDIT margin expansion of 300+ bps to 16%+ — this quarter falls short on both counts. H1 FY27 revenue of ₹190.93 Cr is only 38% of the full-year target, implying H2 would need to average roughly ₹154.5 Cr a quarter, well above the ₹115.78 Cr just printed. PBDIT margin of 9.77% this quarter (8.40% for H1) remains six-to-seven points below the 16%+ guided level. No management press release accompanied this filing to address the gap, so the only read on tone comes from the numbers themselves, which confirm the defensive, cautiously-optimistic posture management struck on the prior call was warranted.
W1
H2 FY27 needs to average ~₹154.5 Cr/quarter in revenue to reach management's ₹500 Cr FY27 guidance, well above the ₹115.78 Cr just printed.
W2
PBDIT margin was 9.77% this quarter (8.40% for H1) against the 16%+ FY27 target — watch for a formal guidance revision on the earnings call.
W3
D&A (₹9.97 Cr) and finance costs (₹7.15 Cr) together more than doubled vs a year ago as new capacity went live; watch whether utilisation rises enough in H2 to absorb this fixed-cost base.
No exceptional items in the Q2FY27 or Q2FY26 quarterly columns (the ₹0.65 Cr labour-code item sits only in the FY26 full-year column, so no adjusted-growth recast is needed); standalone and consolidated are near-identical since the sole subsidiary is an inactive ESOP trust.
Revenue Surges 60%, But Profits Turn Negative—Margin Guidance Crumbling
Synergy's quarterly revenue smashed guidance, driven by strong OEM wins and export acceleration. Yet a ₹5.1 Cr net loss in Q2 reveals severe margin compression: the company's 16%+ PBDIT guidance is undershooting badly, and management hasn't reset expectations.
₹115.8 Cr
+60.8% YoY, +54.1% QoQ
-₹5.1 Cr
loss vs profit prior year (PAT -315.3% YoY)
9.8%
vs 16%+ guided, 15.7% prior year
8.9%
vs 15.6% prior year (down 670 bps)
Synergy Green delivered the quarter in two halves: the first half looks like a win, the second half reads like a warning. Revenue jumped 60.8% year-over-year to ₹115.8 Cr—beating its own 33% FY27 guidance at this pace—and the order book expanded materially (Nordex ₹200+ Cr US orders, Vestas confirmed, Siemens Gamesa and Envision in development). The export mix is accelerating toward 30% of revenue (from 25%), and the company is on track to deliver ₹500 Cr annual revenue. All of this is real. But it published a net loss of ₹5.1 Cr in Q2, and the operating margin collapsed to 9.8% from 15.7% the prior year. That gap is the story: revenue strength masking severe execution trouble.
Where the margin went
The company's prior guidance called for 16%+ PBDIT margins for FY27; H1 delivered 8.9%, Q2 specifically 10.2%. Management blames a toxic trio: raw material inflation (furan resin and pig iron up ~50%), elevated logistics costs (20–30% higher), and electricity tariff increases (20% in Maharashtra, retroactively charged two years). Production volume grew 25.8% YoY, but revenue grew only 20.2% QoQ—the gap is unshipped inventory, sitting on the balance sheet as working capital drag while shipping constraints (Maersk delays, war-induced carrier capacity) slow cash realization. The company passed through roughly 8% of the cost increase to customers; the rest is borne in-house. With 12-month contract locks in place, margin recovery hinges on input price stabilization (slated for Q3 price indexation on CRC and pig iron) and inventory clearance (October shipments ramping to 60–70%).
FY27 revenue ₹500 Cr (33% growth) on track
SupportedQ2 +60.8% YoY, H1 +25.8%. Paced ahead of 33% full-year target.
16%+ PBDIT margins expected full year
OverstatedH1 8.9%, Q2 10.2%. H2 guidance 17–18% EBITDA implies ~13% blended FY27.
Inventory buildup will not impact revenue recognition
SupportedConfirmed: production +25.8% YoY, revenue +20.2% QoQ; unshipped sits as balance-sheet cost.
Export revenues to grow 50% this year; reach 30% of total
SupportedCurrently 25% of revenue; targeting 30%. Nordex US wins and Vestas confirm pull-through.
80% capacity utilization achievable for FY27
SupportedH1 at 75%, targeting 85% by year-end. Weighted ~80% full year remains on track.
What changed on this call
OEM order book expanded materially: Nordex (₹200+ Cr US orders), Vestas confirmed, Siemens Gamesa and Envision in pipeline. Demand stated as 60k+ tons vs 45k capacity—supply constraint, not demand.
Export revenue mix accelerating: targeting 30% of revenue (from 25%), 50% export growth expected. US market now primary driver (GE exited, Nordex entered); tariff advantage vs China is defensible.
Greenfield project pushed out: land acquisition 15–18 months away, full project 2–3 years. Prioritizing stabilization of 45k-ton capacity first; greenfield deprioritized near-term.
Net profitability turned negative: -₹5.1 Cr in Q2 vs profit prior year. Management deflected with EBITDA argument when pressed; targeting 'half-a-percent loss or 0.5% profit' by year-end.
Revenue guidance maintained, margin guidance implicitly cut: FY27 ₹500 Cr (33% growth) reaffirmed, but PBDIT margin guidance downgraded from 16%+ to ~13% blended (per H2 17–18% EBITDA guidance).
The bull-bear ledger
Revenue growth beats guidance pace: +60.8% Q2 YoY vs 33% FY27 guided. Strong demand and OEM traction driving beat.
Major OEM wins provide multi-year visibility: Nordex, Vestas, Siemens Gamesa, Envision wins secured. Non-Chinese supply advantage in US market is structurally defensible.
Capacity constrained, not demand constrained: 60k+ tons demand vs 45k capacity. Greenfield (100k-ton target) provides multi-year growth runway.
Reported profit turned negative despite 60% revenue growth: -₹5.1 Cr Q2 loss signals severe execution challenge. Margin guidance miss is material (16%+ → ~13% blended).
Input cost inflation not yet stabilized: 50% raw material increase, 20–30% logistics elevation. Only 8% passed to customers; rest borne in-house. Recovery contingent on Q3 indexation and cost stabilization.
Inventory buildup and working capital drag: unshipped inventory inflates balance sheet; cash realization delayed to Q3-Q4. Shipping constraints (Maersk, war) adding execution risk.
Heavy depreciation obscuring true cash profit: capex for machine shop and facilities depreciating on P&L; cash profit may be stronger than reported. But EBITDA guidance also undershooting (10% vs 16%+ prior).
Customer concentration risk: Nordex + Vestas account for bulk of new wins. OEM capex cycle slowdown could crater order book near-term.
Greenfield execution and funding deferred: 2–3 year timeline, no formal capex budget disclosed. Land acquisition and capital raise remain execution wildcards.
Risks, ranked by how much they should concern a holder
Input cost inflation and margin pressure persist beyond Q3
HighIf furan resin, pig iron, and logistics costs don't stabilize or if customers resist further price increases, FY27 margins will remain stuck at 10–12% EBITDA (vs 16%+ guided). This would extend net losses and force another guidance cut.
Net profitability not recovered by year-end
HighManagement deflected on when PAT turns positive, pivoting to EBITDA instead. If cash profit doesn't materialize even in H2, it signals the margin miss is structural, not cyclical. Analyst skepticism on this point is warranted.
Inventory and working capital drag extends into Q4
HighIf Maersk delays persist or if ODC constraints continue, the 5.6 percentage-point gap between production and revenue growth will deepen. Unshipped inventory inflates balance sheet and delays cash realization.
OEM capex cycle slowdown (renewable energy macros)
MediumNordex and Vestas account for most new order wins. If renewable energy capex cycles slow globally or if OEM demand shifts to competitors (China, Europe), Synergy's order book could deflate rapidly.
Greenfield project delayed or underfunded
MediumGreenfield land acquisition is 15–18 months away; full capex rollout is 2–3 years. If capital markets tighten or market cap compresses, equity dilution risk rises. Competitors may expand faster, capturing market share.
Rupee depreciation elevates capex and import costs
MediumRupee is down 25% vs RMB in 18 months. While this aids export pricing, it increases capex costs for greenfield and import costs for raw materials. Currency acceleration would delay margin recovery.
How the street is positioned
The stock is trading at ₹555.9, down 20.35% from its all-time high of ₹697.95 and below its 20-, 50-, and 200-day moving averages. The drawdown reflects market skepticism on margin recovery and profitability inflection. FII ownership has collapsed from 0.42% in Q2 FY26 to 0.23% in Q1 FY27—institutional investors are trimming exposure as the margin guidance crumbles. DII has crept up marginally (1.73% in Q1 FY27 vs 1.51% in Q4 FY26), but the overall picture is institutional outflow. Promoter ownership remains rock-solid at 69.5%, which signals long-term conviction but also that the market doesn't trust the near-term recovery narrative. The stock has rallied 32% off its 52-week low of ₹420 but is still down a fifth from its highs—a classic risk-off trade where near-term execution doubt outweighs long-term upside. Post-result momentum is likely muted or negative until Q3 guidance and margin recovery become visible.
1 · Q3 guidance and PBDIT margin recovery
If H1 PBDIT was 8.9% and management guided H2 at 17–18% EBITDA, Q3 will be the first test. Look for PBDIT to rebound toward 12–14% at minimum. If it stays stuck at 10–11%, the margin miss is structural, and the bear case accelerates.
2 · Net profit inflection and cash conversion
Management targeted 'half-a-percent loss or 0.5% profit' by year-end. Q3 should show path to positive PAT; if not, the market will interpret it as lack of cash profit visibility and re-rate the stock lower.
3 · Inventory clearance and working capital normalization
October shipments ramped to 60–70%; Q3 should show material inventory rundown. If unshipped inventory persists beyond Q3, the working capital drag will extend into Q4 and delay cash realization.
4 · Greenfield land acquisition and capex detail
The 15–18 month timeline for greenfield land acquisition is vague. Any concrete announcement on land, capex budget, or equity raise would clarify execution risk and de-risk the long-term thesis.
Synergy Green Industries is a steady long-term execution story turning into a near-term question mark. Revenue growth is real and impressive—60.8% YoY well ahead of the 33% guidance—and the OEM order book expansion (Nordex, Vestas, Siemens Gamesa) provides multi-year visibility. But the company's inability to defend profitability in a quarter of 60% revenue growth is a red flag. Margin guidance has been implicitly slashed from 16%+ to ~13% blended, and management's deflection on net losses to EBITDA suggests limited confidence in cash profit recovery. The stock's 20% drawdown from all-time high is not entirely unwarranted; near-term execution risk is material. The single number to track from here is Q3 PBDIT margin: if it rebounds toward 12–14%, the margin miss is cyclical and the bull case remains intact. If it stalls at 10–11%, the bear case accelerates and the stock has further downside.